Mark Oki
Directeur Financier/CFO chez AYTU BIOPHARMA, INC.
Fortune : 27 740 $ au 30/06/2024
Profil
Mr. Mark K.
Oki, CPA, is a Chief Financial Officer, Secretary & Treasurer at Aytu Biopharma, Inc. and a Chief Financial Officer at Neos Therapeutics, Inc. Mr. Oki was previously employed as a Chief Financial & Accounting Officer, Senior VP by VIVUS, Inc., a CFO, Secretary & Senior VP-Finance by Alexza Pharmaceuticals, Inc., a Controller by Pharmacyclics, Inc., and an Assistant Controller by Incyte Genomics, Inc. He received his undergraduate degree from San Jose State University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AYTU BIOPHARMA, INC.
0,16% | 29/04/2024 | 9 500 ( 0,16% ) | 27 740 $ | 30/06/2024 |
Postes actifs de Mark Oki
| Sociétés | Poste | Début |
|---|---|---|
| AYTU BIOPHARMA, INC. | Directeur Financier/CFO | 17/01/2022 |
| NEOS THERAPEUTICS, INC. | Directeur Financier/CFO | - |
Anciens postes connus de Mark Oki
| Sociétés | Poste | Fin |
|---|---|---|
| ALEXZA PHARMACEUTICALS, INC. | Directeur Financier/CFO | 16/10/2015 |
| PHARMACYCLICS, INC. | Comptroller/Controller/Auditor | 01/04/2006 |
| INCYTE CORPORATION | Corporate Officer/Principal | 01/01/2001 |
| VIVUS, INC. | Directeur Financier/CFO | - |
Formation de Mark Oki
| San Jose State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| INCYTE CORPORATION | Health Technology |
| AYTU BIOPHARMA, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Alexza Pharmaceuticals, Inc.
 Alexza Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexza Pharmaceuticals, Inc. is a pharmaceutical company. It focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. Its product candidates are AZ-002 and AZ-007. The company was founded by Alejandro C. Zaffaroni in 2000 and is headquartered in Mountain View, CA. | Health Technology |
Pharmacyclics LLC
 Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
VIVUS, Inc.
 VIVUS, Inc. Pharmaceuticals: MajorHealth Technology VIVUS, Inc. engaged in the development and commercialization of novel therapeutic products. The firm’s products were indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and it was headquartered in Campbell, CA. | Health Technology |
Neos Therapeutics, Inc.
 Neos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX. | Health Technology |
